This HTML5 document contains 27 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Subject Item

n2:w

rdf:type

bibo:Article rdac:C10001

dcterms:isPartOf

n9:w

dcterms:subject

n8:gynecologictumors n10:ipchemotherapy n10:ovariancancer n10:toxicity n8:originalarticles n10:qualityofcare

dcterms:title

From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer

rdaw:P10072

n16:web n16:print

vivo:relatedBy

n12:4 n12:6 n12:5 n12:1 n12:2 n12:3

marcrel:aut

n6:3238581be13d1cc1bea1cc2875f624b3 n2:longhj n17:id n2:hartmannl n2:gallenbergm n2:nordquistd

dcterms:abstract

Background: The objective of the study was to evaluate completion rates and toxic effects of an i.p. chemotherapy regimen in a cross-section of nonselected patients with ovarian cancer (OC). Patients and methods: All patients with stage IIIC OC consecutively operated at our institution from January 2006 to December 2007 were prospectively collected and analyzed. Results: Eighty-nine patients with stage IIIC OC optimally debulked were evaluated for this study. An i.p. port was primarily placed in 53 of 89 (60%), and i.p. chemotherapy was recommended in 55 patients. Reasons for not recommending i.p. chemotherapy in patients optimally debulked included postoperative complications (n = 7: 8%), poor nutritional/functional status (n = 5: 6%), and extensive surgery including bowel resection (n = 9: 10%). Thirty-three patients (33/55: 60%) recommended to receive i.p. chemotherapy-initiated i.p. treatment. Fifty-two percent of those beginning i.p. therapy (17/33) received three or more cycles with 36% (12/33) successfully completing six cycles. Reasons for discontinuation included grade 3-4 nephrotoxicity in 3 of 21 (14%), febrile neutropenia/sepsis in 3 of 21 (14%), port infection or malfunction in 8 of 21 (38%). Conclusions: The i.p. chemotherapy regimen used in a consecutive cohort of patients carries could be completed in only a small percentage of patients. Less toxic regimens with higher acceptability should be considered.

hub:articleType

n18:researcharticle

hub:isPartOfThisJournal

n4:w